WHITESBORO, N.Y — Starting next Wednesday, eligible Medicare patients will be able to enroll in the new Medicare GLP-1 Bridge Program offered by Kinney Drugs.
The pilot program will provide qualifying customers access to medications, including Wegovy, Zepbound, and Fundayo, for a monthly copay of $50 through the end of 2027.
Shannon Miller, the Kinney Drugs vice president of healthcare operations, said that the program is designed to expand access to weight-loss treatments for Medicare patients who may not have previously had coverage for the medications.
To qualify, patients must be enrolled in an eligible Medicare Part D plan and meet certain health requirements.
People interested in participating need to schedule an appointment with their healthcare provider to determine whether they meet the eligibility requirements.
Starting next Wednesday, eligible Medicare patients will be able to enroll in the new Medicare GLP-1 Bridge Program offered by Kinney Drugs.